AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 7998585
Drug: Rilmenidine 1
RxNorm normalized name: rilmenidine 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rilmenidine 1 mg at the end of each dialysis session (Group 3)
Trial: 7998585
Drug: Rilmenidine 1
RxNorm normalized name: rilmenidine 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rilmenidine 1 mg daily (Group 1)
Trial: 3377142
Drug: Inhaled dipyridamole
RxNorm normalized name: Dipyridamole
DrugBank: Dipyridamole (DB00975)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Inhaled dipyridamole
Trial: 31205187
Drug: PF‐02545920 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF‐02545920 5 mg
Trial: 31205187
Drug: PF‐02545920 15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF‐02545920 15 mg
Trial: 15483411
Drug: Low-dose albumin
RxNorm normalized name: Albumin Aggregated
DrugBank: Albumin Aggregated (DB14230)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose albumin (control group)
Trial: 15483411
Drug: Moderate-dose albumin
RxNorm normalized name: Albumin Aggregated
DrugBank: Albumin Aggregated (DB14230)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate-dose albumin (control group)
Trial: 9081352
Drug: Prophylactic cranial
RxNorm normalized name: geranial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic cranial irradiation (PCI) at a dose of 33 Gy/11 fractions (45 patients) and 25 Gy/11 fractions (112 patients)
Trial: 1670734
Drug: Aspirin taken
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin taken at least once during the week before the first symptom
Trial: 1670734
Drug: Paracetamol, propyphenazone,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol, propyphenazone, and dipyrone
Trial: 6339708
Drug: Single-dose amoxicillin
RxNorm normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single-dose amoxicillin therapy
Trial: 6339708
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy (10-day course of amoxicillin)
Trial: 6339708
Drug: Antibody-coated bacteria
RxNorm normalized name: digoxin antibodies Fab fragments
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibody-coated bacteria assay
Trial: 31864884
Drug: Knowledge test
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Knowledge test administered to pharmacists.
Trial: 28426350
Drug: Lenalidomide maintenance
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lenalidomide maintenance 25 mg/d for 21 days of every 28-day cycle for 24 months
Trial: 18046048
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg oral testosterone enanthate (TE) twice daily plus 0.5 mg dutasteride daily
Trial: 18046048
Drug: 800 mg
RxNorm normalized name: bran 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 mg oral testosterone enanthate (TE) once daily plus 0.5 mg dutasteride daily
Trial: 15271105
Drug: Fixed combination
RxNorm normalized name: Progestogens and estrogens, fixed combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed combination dorzolamide-timolol (Cosopt)
Trial: 15271105
Drug: Concomitant administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Concomitant administration of 2% dorzolamide and 0.5% timolol
Trial: 15271105
Drug: Fixed combination
RxNorm normalized name: Progestogens and estrogens, fixed combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed combination dorzolamide-timolol (Cosopt) in replacement study
Trial: 1614074
Drug: Felodipine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Felodipine (10 mg, single oral dose)
Trial: 6540130
Drug: IgG therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IgG therapy
Trial: 3487296
Drug: Intravenous administration
RxNorm normalized name: intravenous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of verapamil prior to aortic cross‐clamping (Group 1)
Trial: 3487296
Drug: Intravenous verapamil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous verapamil plus verapamil in the cardioplegic solution (Group 2)
Trial: 3487296
Drug: Verapamil in
RxNorm normalized name: verapamil Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil in the cardioplegic solution only (Group 3)
Trial: 24164779
Drug: Sucrose drinks
RxNorm normalized name: Sucrose
DrugBank: Sucrose (DB02772)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sucrose drinks (4 × 250 ml, total 1800 kJ/d)
Trial: 24164779
Drug: Aspartame drinks
RxNorm normalized name: Aspartame
DrugBank: Aspartame (DB00168)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspartame drinks (4 × 250 ml)
Trial: 16189197
Drug: High-dose GH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose GH (0.3 mg . kg(‐1) . d(‐1))
Trial: 16189197
Drug: High-dose DEXA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose DEXA
Trial: 16189197
Drug: Lower dose
RxNorm normalized name: flowers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower dose DEXA
Trial: 1714507
Drug: 6-methylmercaptopurine riboside
RxNorm normalized name: NICOTINAMIDE RIBOTIDE
DrugBank: Methylthioinosine (DB02896)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6-methylmercaptopurine riboside (MMPR) at 75 mg/m2
Trial: 1714507
Drug: 6-methylmercaptopurine riboside
RxNorm normalized name: NICOTINAMIDE RIBOTIDE
DrugBank: Methylthioinosine (DB02896)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6-methylmercaptopurine riboside (MMPR) at 150 mg/m2
Trial: 1714507
Drug: 6-methylmercaptopurine riboside
RxNorm normalized name: NICOTINAMIDE RIBOTIDE
DrugBank: Methylthioinosine (DB02896)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6-methylmercaptopurine riboside (MMPR) at 225 mg/m2
Trial: 30446250
Drug: CPAP therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPAP therapy (n=151) for 12 weeks
Trial: 30446250
Drug: Conservative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative treatment (n=156) for 12 weeks
Trial: 24768191
Drug: Extended-release niacin
RxNorm normalized name: niacin Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release niacin (ERN) 1 g/d
Trial: 24768191
Drug: Extended-release niacin
RxNorm normalized name: niacin Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release niacin with laropiprant (ERN/LRP) 1 g/20 mg
Trial: 16187006
Drug: Propionyl-L-carnitine (PC)
RxNorm normalized name: glycine propionyl-L-carnitine
DrugBank: Levocarnitine propionate (DB15980)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propionyl-L-carnitine (PC) 24 mg/kg b.w.
Trial: 16187006
Drug: L-carnitine (LC)
DrugBank: Levocarnitine (DB00583)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: L-carnitine (LC) 20 mg/kg b.w.
Trial: 9161626
Drug: Famciclovir 500
RxNorm normalized name: famciclovir 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Famciclovir 500 mg three times daily for seven days
Trial: 9161626
Drug: Famciclovir 500
RxNorm normalized name: famciclovir 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Famciclovir 500 mg three times daily for seven days among patients 50 years or older
Trial: 30171698
Drug: 0.03% resiquimod
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.03% resiquimod gel once-daily application three times per week for 4 weeks
Trial: 30171698
Drug: 0.03% resiquimod
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.03% resiquimod gel seven times within 2 weeks
Trial: 30171698
Drug: 0.03% resiquimod
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.03% resiquimod gel five times for 1 week
Trial: 30171698
Drug: 0.01% resiquimod
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.01% resiquimod gel three times per week up to a biological end point or for a maximum duration of 8 weeks
Trial: 30171698
Drug: 0.03% resiquimod
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.03% resiquimod gel three times per week up to a biological end point or for a maximum duration of 8 weeks
Trial: 25833957
Drug: Daunorubicin 90
RxNorm normalized name: daunorubicin
DrugBank: Daunorubicin (DB00694)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Daunorubicin 90 mg/m2
Trial: 25833957
Drug: Daunorubicin 60
RxNorm normalized name: daunorubicin
DrugBank: Daunorubicin (DB00694)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Daunorubicin 60 mg/m2
Trial: 19167733
Drug: Thalidomide (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thalidomide (200 mg per day) during oral phase A
Trial: 19167733
Drug: Placebo during
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo during oral phase A
Trial: 19167733
Drug: Thalidomide (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thalidomide (200 mg per day) during oral phase B
Trial: 19167733
Drug: Placebo during
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo during oral phase B
Trial: 14641105
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid 5 mg/day for 8 weeks
Trial: 11248742
Drug: Growth Hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth Hormone (GH) treatment at a mean dose of 0.32 mg/kg per week for 1 year
Trial: 11248742
Drug: Pre-treatment serum
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-treatment serum total IGF‐I levels
Trial: 8201372
Drug: Hydrazine sulfate
RxNorm normalized name: Hydrazine Sulfate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrazine sulfate 60 mg three times per day orally
Trial: 26098419
Drug: Rhodiola crenulata
RxNorm normalized name: RHODIOLA CRENULATA ROOT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rhodiola crenulata (RC) 250 mg twice/day (n=38)
Trial: 26098419
Drug: Placebo (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (250 mg twice/day) (n=19)
Trial: 19894330
Drug: Calcium 1500
RxNorm normalized name: calcium citrate 1500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium 1500 g/day + alfacalcidol 0.5 mg/day
Trial: 19894330
Drug: Calcium 1500
RxNorm normalized name: calcium citrate 1500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium 1500 g/day + placebo
Trial: 16720058
Drug: Vinorelbine (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vinorelbine (25 mg/m2 on days 1 and 8) and cisplatin (80 mg/m2 on day 8) every 3 weeks
Trial: 15100375
Drug: Normal hemoglobin
RxNorm normalized name: Abnormal hemoglobin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal hemoglobin group (target hemoglobin of 14 +/- 1 g/dl)
Trial: 15100375
Drug: Anemic hemoglobin
RxNorm normalized name: HEMOGLOBIN
DrugBank: Hemoglobin (DB04945)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anemic hemoglobin group (target hemoglobin of 10 +/- 1 g/dl)
Trial: 8547417
Drug: Interferon alpha
RxNorm normalized name: Interferon alpha-2a
DrugBank: Interferon alfa-2a (DB00034)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon alpha (1 megaunit weekly for 4 weeks)
Trial: 2501813
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg nicotine gum (Nicorette; average of 6.9 pieces per day)
Trial: 30496578
Drug: Active vitamin
RxNorm normalized name: OCTOCRYLENE 70 mg in 1 mL / HOMOSALATE 50 mg in 1 mL / OCTISALATE 50 mg in 1 mL / AVOBENZONE 30 mg in 1 mL TOPICAL CREAM [Garnier SkinActive Vitamin(E) C UV Brightening Daily Broad Spectrum SPF 30]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active vitamin D3 (adjusted to maintain serum 25(OH)D >75 nmol/L)
Trial: 26034983
Drug: ESM self‐monitoring
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ESM self‐monitoring combined with weekly PA‐focused feedback sessions
Trial: 26034983
Drug: ESM self‐monitoring
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ESM self‐monitoring combined with six weekly sessions without feedback
Trial: 24955642
Drug: Astaxanthin (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Astaxanthin (2 mg/day) combined with collagen hydrolysate (3 g/day)
Trial: 22499290
Drug: Chlortalidone (12.5-25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlortalidone (12.5-25 mg daily)
Trial: 22499290
Drug: Other antihypertensive
RxNorm normalized name: Other antihypertensives
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other antihypertensive medications (excluding thiazides)
Trial: 17620073
Drug: 3-year subcutaneous
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-year subcutaneous specific immunotherapy (SIT) with standardized allergen extracts of grass and/or birch
Trial: 17620073
Drug: No specific
RxNorm normalized name: Oregano specific IgE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No specific immunotherapy (Control)
Trial: 9836561
Drug: Testicular androgen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Testicular androgen ablation (bilateral orchiectomy in 15 and luteinizing hormone‐releasing hormone analogue in 3)
Trial: 9836561
Drug: Finasteride (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Finasteride (5 mg/day) alone or in combination with flutamide (250 mg three times a day)
Trial: 1918555
Drug: General coping
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General coping preparation package (PREP)
Trial: 1918555
Drug: Routine clinic
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine clinic treatment only
Trial: 6173904
Drug: Chemotherapy (MOPP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (MOPP + LDB)
Trial: 6173904
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment (MOPP + LDB + XRT)
Trial: 30902420
Drug: 10 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 μg (400 IU) vitamin D supplementation
Trial: 30902420
Drug: 30 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 μg (1200 IU) vitamin D supplementation
Trial: 30902420
Drug: High cord
RxNorm normalized name: Bos taurus umbilical cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High cord blood 25-hydroxyvitamin D (≥100 nmol/L)
Trial: 24413638
Drug: Subcutaneous interferon
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous interferon β‐1a, 44 μg sc three times weekly or once weekly, for 24 months or until diagnosis of clinically definite multiple sclerosis (CDMS)
Trial: 17588396
Drug: Methylprednisolone (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylprednisolone (15 mg/kg)
Trial: 11454380
Drug: 900 mg
RxNorm normalized name: diosmin 900 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 900 mg gemfibrozil daily for 6 weeks
Trial: 11454380
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg fenofibrate daily for 6 weeks
Trial: 2808867
Drug: Plain lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plain lidocaine solution
Trial: 1208040
Drug: Glutathione‐bicarbonate‐Ringer's (GBR)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glutathione‐bicarbonate‐Ringer's (GBR) solution
Trial: 26130623
Drug: Oral ambroxol
RxNorm normalized name: ambroxol
DrugBank: Ambroxol (DB06742)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ambroxol (40 mg/kg/day, in four divided doses)
Trial: 21712501
Drug: No/low intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No/low intervention dose
Trial: 21712501
Drug: Medium intervention
RxNorm normalized name: TRIGLYCERIDES,MEDIUM CHAIN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium intervention dose
Trial: 21712501
Drug: High intervention
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High intervention dose
Trial: 18618371
Drug: 5 microg
RxNorm normalized name: Digoxin 125 microgram oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 microg ramosetron hydrochloride once daily for 12 weeks
Trial: 8103648
Drug: General anesthesia
RxNorm normalized name: Ethers for general anesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General anesthesia with thiopental (2‐4 mg/kg) and low fentanyl dose (5 micrograms/kg)
Trial: 8103648
Drug: General anesthesia
RxNorm normalized name: Ethers for general anesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General anesthesia with thiopental (2‐4 mg/kg) and high fentanyl dose (30 micrograms/kg)
Trial: 3785608
Drug: Best available
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Best available medical therapy
Trial: 22494879
Drug: Nicotine and
RxNorm normalized name: lovastatin and nicotinic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine and alcohol co-administration
Trial: 16234451
Drug: Pressure topical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pressure topical anaesthesia
Trial: 16234451
Drug: Injection anaesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection anaesthesia
Trial: 12167550
Drug: Risperidone (0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risperidone (0.75 mg)
Trial: 10459902
Drug: Cationic lipid-mediated
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cationic lipid-mediated CFTR gene transfer (active treatment)
Trial: 31759193
Drug: PQ912 treatment
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PQ912 treatment (glutaminylcyclase inhibitor)
Trial: 19784511
Drug: 4 L.min‐1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 L.min‐1 of oxygen (Group O)
Trial: 10642349
Drug: Candesartan cilexetil
RxNorm normalized name: Candesartan Cilexetil
DrugBank: Candesartan cilexetil (DB00796)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Candesartan cilexetil (8 to 16 mg daily)
Trial: 3520129
Drug: Maltitol (10g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maltitol (10g 3 times daily for 5 days)
Trial: 31545373
Drug: Combination therapies
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapies in single-arm trials
Trial: 31545373
Drug: Combination therapies
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapies with observed rates 10 percentage points higher than upper targets
Trial: 31545373
Drug: Single-arm combination
RxNorm normalized name: ARM-210
DrugBank: ARM-210 (DB16944)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-arm combination trials
Trial: 22257614
Drug: Verapamil SR
RxNorm normalized name: Dom-Verapamil SR
DrugBank: Verapamil (DB00661)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Verapamil SR treatment strategy
Trial: 22257614
Drug: Atenolol treatment
RxNorm normalized name: Atenolol
DrugBank: Atenolol (DB00335)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atenolol treatment strategy
Trial: 22257614
Drug: Both treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatment strategies
Trial: 20169490
Drug: Water suppression
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Water suppression system (0.13, 0.06, 0.03, or 0.02 L/sec of water)
Trial: 20169490
Drug: No control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No control treatment
Trial: 18023335
Drug: Formoterol (2x9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formoterol (2x9 microg lower dose; 6x9 microg higher dose)
Trial: 18023335
Drug: Salbutamol (3x400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salbutamol (3x400 microg lower dose; 9x400 microg higher dose)
Trial: 12757028
Drug: Ozonated autohemotherapy
RxNorm normalized name: ozone
DrugBank: Ozone (DB12510)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ozonated autohemotherapy with ozone concentration 50 microg/ml per gram of blood
Trial: 11134094
Drug: 0.25 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25 mg/day micronized 17ss-estradiol
Trial: 11134094
Drug: 0.5 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg/day micronized 17ss-estradiol
Trial: 11134094
Drug: 1.0 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 mg/day micronized 17ss-estradiol
Trial: 9079233
Drug: Lisinopril treatment
RxNorm normalized name: Lisinopril
DrugBank: Lisinopril (DB00722)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lisinopril treatment
Trial: 9079233
Drug: Lisinopril/hydrochlorothiazide treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lisinopril/hydrochlorothiazide treatment
Trial: 9079233
Drug: Intensified non-pharmacological
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensified non-pharmacological treatment
Trial: 9079233
Drug: Previous or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Previous or adjusted medication
Trial: 3717956
Drug: Regimen A
RxNorm normalized name: CHLOROXYLENOL 5 g in 1000 mL TOPICAL SOAP [REGIMEN ANTIMICROBIAL]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regimen A (CDDP 75 mg/m2 and ADM 50 mg/m2 every 4 weeks)
Trial: 3717956
Drug: Regimen B
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regimen B (CDDP 75 mg/m2, ADM 50 mg/m2, plus VCR 1.4 mg/m2 on day 1 and 0.7 mg/m2 on day 7 every 4 weeks)
Trial: 30516797
Drug: Prolonged exposure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolonged exposure therapy plus sertraline